Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion pushed from Apr 30, 2026 to Apr 30, 2030 Show 4 more changesShow less
    • Eligibility criteria shortened, about 8 words
    • Secondary endpoints: details revised at 3 of 4 entries
    • Study description shortened, about 8 words
    • Publications: details revised at 1 of 1 entry
  2. Re-verified, no change to tracked fieldsv42
  3. Results first posted: Feb 27, 2026
    • Secondary endpoints revised (4)
    • Primary endpoint revised
    v41
  4. Re-verified, no change to tracked fieldsv40
  5. Study completion date: Mar 31, 2025 to Apr 30, 2026v39
Show 37 earlier versionsHide 37 earlier versions
  1. 5 versions Re-verified since Apr 9, 2024, no change to tracked fieldsv34-v38
  2. Primary and study completion dates: Mar 2025 to Mar 31, 2025v33
  3. Primary and study completion dates: Nov 1, 2023 to Mar 2025v32
  4. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 72 to confirmed 53
    • Site details revised
    v31
  5. 2 versions Re-verified since Aug 10, 2023, no change to tracked fieldsv29-v30
  6. Primary completion date: Nov 1, 2022 to Nov 1, 2023v28
  7. Re-verified, no change to tracked fieldsv27
  8. Primary completion date: Nov 1, 2021 to Nov 1, 2022
    • Study completion date: Nov 1, 2021 to Nov 1, 2023
    v26
  9. Re-verified, no change to tracked fieldsv25
  10. Eligibility criteria expanded, about 7 wordsv24
  11. Re-verified, no change to tracked fieldsv23
  12. Enrollment target: 40 to 72
    • Eligibility criteria revised
    • Study description revised
    v22
  13. Primary and study completion dates: Jul 31, 2019 to Nov 1, 2021v21
  14. Primary endpoints: 2 to 1v20 Show 8 more changesShow less
    • Primary and study completion dates: Jul 2019 to Jul 31, 2019
    • Interventions: Lenalidomide (Drug), Pembrolizumab (Drug), Rituximab (Drug) to Laboratory Biomarker Analysis (Other), Lenalidomide (Drug), Pembrolizumab (Biological), Rituximab (Biological)
    • Eligibility criteria expanded, about 56 words
    • Secondary endpoints: 8 to 4
    • Study description expanded, about 450 words
    • Study site revised
    • Collaborators: 2 to 1
    • Study title expanded, about 7 words
  15. Trial status: Active, Not Recruiting to Recruiting
    • Enrollment target: 32 to 40
    • Site details revised
    v19
  16. Eligibility criteria shortened, about 37 words
    • Study description shortened, about 453 words
    v18
  17. Study completion date: Jul 2020 to Jul 2019v17
  18. 2 versions Re-verified since Feb 12, 2018, no change to tracked fieldsv15-v16
  19. Study completion date: Jul 2019 to Jul 2020
    • Study description shortened, about 192 words
    v14
  20. Re-verified, no change to tracked fieldsv13
  21. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 100 to confirmed 32
    • Start date: Jul 2015 to Jul 31, 2015
    • Site details revised
    v12
  22. Study description shortened, about 23 wordsv11
  23. Primary and study completion dates: Jul 2018 to Jul 2019v10
  24. Enrollment target: 30 to 100v9 Show 6 more changesShow less
    • Primary endpoints: 1 to 2
    • Interventions: Pembrolizumab (Drug), Rituximab (Drug) to Lenalidomide (Drug), Pembrolizumab (Drug), Rituximab (Drug)
    • Eligibility criteria expanded, about 161 words
    • Secondary endpoints expanded, about 179 words
    • Study description expanded, about 126 words
    • Study arms: 1 to 2
  25. Re-verified, no change to tracked fieldsv8
  26. Primary completion date: Jul 2017 to Jul 2018
    • Study completion date: Jul 2018
    v7
  27. 3 versions Re-verified since Feb 1, 2016, no change to tracked fieldsv4-v6
  28. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Sep 2017 to Jul 2017
    • Start date: Sep 2015 to Jul 2015
    • Site details revised
    v3
  29. Eligibility criteria revisedv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial studies how well rituximab and pembrolizumab with or without lenalidomide works in treating patients with follicular lymphoma and diffuse large B-cell lymphoma that has returned after a period of improvement. Immunotherapy with monoclonal antibodies, such as rituximab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving rutuximab with pembrolizumab and lenalidomide may work better at treating follicular lymphoma and diffuse large B-cell lymphoma.
Trial Details
NCT Number NCT02446457
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma
Related terms Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
Enrollment 53 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov